Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Study

Seprase, Dipeptidyl Peptidase IV and Urokinase-Type Plasminogen Activator Expression in Dysplasia and Invasive Squamous Cell Carcinoma of the Esophagus

A Study of 229 Cases from Anyang Tumor Hospital, Henan Province, China

Goscinski M.A.a · Suo Z.H.b · Nesland J.M.b · Chen W.-T.d · Zakrzewska M.c, e · Wang J.f · Zhang S.g · Flørenes V.A.b · Giercksky K.-E.a

Author affiliations

aDepartment of Surgery, bDivision of Pathology, and cCentre for Cancer Biomedicine and Department of Biochemistry, Rikshospitalet-Radiumhospitalet Medical Centre, Medical Faculty, University of Oslo, Oslo, Norway; dDepartment of Medicine, Stony Brook University, Stony Brook, N.Y., USA; eFaculty of Biotechnology, University of Wroclaw, Wroclaw, Poland; Departments of fOncology and gPathology, Anyang Tumor Hospital, Anyang, China

Related Articles for ""

Oncology 2008;75:49–59

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: December 27, 2007
Accepted: April 18, 2008
Published online: September 12, 2008
Issue release date: September 2008

Number of Print Pages: 11
Number of Figures: 7
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Objective: Seprase, dipeptidyl peptidase IV (DPPIV) and urokinase-type plasminogen activator (uPA) play a crucial role in the degradation of the extracellular matrix and in the progression of various human tumors. However, their pathophysiologic significance in esophageal carcinoma has not yet been fully elucidated. Methods: The expression of seprase, DPPIV and uPA in esophageal dysplasia, squamous cell carcinoma (SCC) and normal epithelium was examined by immunohistochemistry. Results: Seprase, DPPIV and uPA immunoreactivity was found in dysplastic and cancer cells as well as in stromal cells adjacent to dysplasia and cancer sites, but not in normal epithelium. We found a significant association between uPA expression and sex, tumor size and histological classification in carcinomas. High expression of DPPIV in cancer cells correlated with longer survival of the patients. No significant associations between seprase and clinicopathological features either in dysplasia or in carcinomas were found. Finally, we demonstrated higher levels of seprase, DPPIV and uPA in SCC cell lines than in normal esophageal epithelial cell lines. Conclusions: Our results showed that seprase, DPPIV and uPA are expressed in both premalignant and malignant forms of SCC, but are lacking in normal esophageal epithelia, suggesting that they are involved in SCC neoplastic progression.

© 2008 S. Karger AG, Basel


References

  1. Chen W-T, Kelly T: Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003;22:259–269.
  2. Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990;87:7235–7239.
  3. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91:5657–5661.
  4. Aoyama A, Chen WT: A 170-kDa membrane-bound protease is associated with expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci USA 1990;87:8296–8300.
  5. Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, Chen WT: A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994;54:5702–5710.
  6. Goldstein LA, Ghersi G, Pineiro-Sanchez ML, Salamone M, Yeh Y, Flessate D, Chen W-T: Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta 1997;1361:11–19.
    External Resources
  7. Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Tran H, Argraves WS, Chen W-T: Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997;272:7595–7601.
  8. Kelly T, Kechelava S, Rozypal TL, West KW, Korourian S: Seprase, a membrane-bound protease is overexpressed by invasive and microinvasive ductal carcinoma cells of human breast cancer. Mod Pathol 1998;11:855–863.
  9. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H: Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001;95:67–92.
  10. Iwasa S, Jin X, Okada K, Mitsumata M, Ooi A: Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 2003;199:91–98.
  11. Okada K, Chen W-T, Iwasa S, Jin X, Yamane T, Ooi A: Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology 2003;65:363–370.
  12. Hopsu-Havu VK, Glenner GG: A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966;7:197–201.
  13. Busek P, Malik R, Sedo A: Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004;36:408– 421.
  14. Yaron A, Naider F: Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 1993;28:31–81.
  15. Sedo A, Malik R, Drbal K, Lisa V, Vlasicova K, Mares V: Dipeptidyl peptidase IV in two human glioma cell lines. Eur J Histochem 2001;45:57–63.
  16. Ghersi G, Chen W-T, Lee EW, Zukowska Z: Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides 2001;22:453–458.
  17. De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today 1999;20:367–375.
  18. Drucker DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003;12:87–100.
  19. Cheng HC, Abdel-Ghany M, Pauli BU: A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003;278:24600–24607.
  20. Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU: Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer calls via tumor cell surface-associated fibronectin. J Biol Chem 1998;273:24207–24215.
  21. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE: Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 2006;16:161–175.
  22. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen W-T: Seprase-DPPIV association and prolyl peptidase and gelatinase activities of the protease complex. Adv Exp Med Biol 2003;524:87–94.
  23. Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen W-T: The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006;66:4652–4661.
  24. Behrendt N, Ronne E, Dano K: The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995;376:267–279.
  25. Artym VV, Kindzelski AL, Chen W-T, Petty HR: Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta 1 integrins and cytoskeleton. Carcinogenesis 2002;23:1592–1601.
    External Resources
  26. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A: The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 1988;50:527–535.
  27. Torzewski M, Sarbia M, Verreet P, Dutkowski P, Heep H, Willers R, Gabbert HE: Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinoma of esophagus. Clin Cancer Res 1997;3:2263–2268.
  28. Huang Y, Wang S, Kelly T: Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004;64:2712–2716.
  29. Mori Y, Kono K, Matsumoto Y, Fujii H, Yamane T, Mitsumata M, Chen W-T: The expression of type II transmembrane serine protease (seprase) in human gastric carcinoma. Oncology 2004;67:411–419.
  30. Wesley UV, Albino AP, Tiwari S, Houghton AN: A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999;190:311–322.
  31. Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN: FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 2004;23:5435–5446.
  32. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S: Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 2005;1751:45–51.
  33. Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C, Sedo A: Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol 2007;31:785–792.
  34. WHO: WHO Histological Typing of Esophageal and Gastric Tumors. Geneva, WHO, 1990, pp 20–26.
  35. UICC: TNM Atlas: An Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. Digestive System Tumors, ed 5. Heidelberg, Springer, 2005, pp 74–83.
  36. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen W-T: Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res 2006;66:9977–9985.
  37. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
  38. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
  39. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
  40. Van der Veken P, Haemers A, Augustyns K: Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007;7:621–635.
  41. Urade M, Komatsu M, Yamaoka M, Fukasawa K, Harada M, Mima T, Matsuya T: Serum dipeptidyl peptidase activities as a possible marker of oral cancer. Cancer 1989;64:1274–1280.
  42. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller DJ, Fink U, Siewert JR: Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998;4:1755–1763.
  43. Uematsu T, Tanaka H, Yamaoka M, Furusawa K: Effect of oral squamous cell-carcinoma-derived TGF-beta 1 on CD26/DPPIV expression in T cells. Anticancer Res 2004;24:619–624.
  44. Moehrle MC, Schlagenhauff BE, Klesen C, Rassner G: Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histological study. J Cutan Pathol 1995;22:241–247.
  45. Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, Dano K: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984;99:752–757.
  46. Kohga S, Harvey S, Marcus G: Localisation of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 1985;45:1787–1796.
  47. Gaylis FD, Keer HD, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM: Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989;142:193–198.
  48. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P: Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005;5:10.
    External Resources
  49. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED: Epithelial-stromal interaction in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer 1992;70:2115–2120.
  50. Busek P, Stremenova J, Sedo A: Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors – good or evil? Front Biosci 2008;13:2319–2326.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: December 27, 2007
Accepted: April 18, 2008
Published online: September 12, 2008
Issue release date: September 2008

Number of Print Pages: 11
Number of Figures: 7
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.